Month: May 2024

To Nasdaq Copenhagen Change of address As of 27 May 2024 the companies Nykredit Realkredit A/S, Nykredit Bank A/S and Totalkredit A/S will change address to Sundkrogsgade 25DK-2150 Nordhavn ContactQuestions may be addressed to Press Relations, tel +45 31 21 06 39.AttachmentFlytning – Nykredit Realkredit Bank og Totalkredit_uk

To Nasdaq Copenhagen Change of address As of 27 May 2024 the companies Nykredit Realkredit A/S, Nykredit Bank A/S and Totalkredit A/S will change address to Sundkrogsgade 25DK-2150 Nordhavn ContactQuestions may be addressed to Press Relations, tel +45 31 21 06 39.AttachmentFlytning – Nykredit Realkredit Bank og Totalkredit_uk

To Nasdaq Copenhagen Change of address As of 27 May 2024 the companies Nykredit Realkredit A/S, Nykredit Bank A/S and Totalkredit A/S will change address to Sundkrogsgade 25DK-2150 Nordhavn ContactQuestions may be addressed to Press Relations, tel +45 31 21 06 39.AttachmentFlytning – Nykredit Realkredit Bank og Totalkredit_uk

The Novian software and IT infrastructure services group had aggregated revenue of EUR 40.3 million in 2023, an increase of 21.9% compared to 2022. The group’s EBITDA for last year was EUR 1.2 million and shrank 18.5% from the previous year. The operating profit for 2023 was EUR 0.14 million and was 72.2% smaller than in 2022. “As demand for digitalization grows, we are striving to create value for clients by addressing their needs and providing advanced programming and IT infrastructure solutions, seeking ways to effectively apply innovations, including AI. We are delighted that our steady work in this direction is contributing to business growth on both a national and international scale,” said Tomas Vitkus, the CEO of the Novian group. He added that one important competence of Novian is its experience developing modern technological...

Grenoble, May 27, 2024 – 7:30 am CEST – McPhy Energy, specialized in low-carbon hydrogen production and distribution equipment (electrolyzers and refueling stations), today announces that Hytlantic and McPhy agreed to terminate their cooperation in the frame of the GreenH2Atlantic project. The decision follows an in-depth assessment of the activities performed and outcomes of the partnership between Hytlantic and McPhy over the past few years during project development, and the outlook for the progress of those activities and results going forward. Hytlantic remains committed to the development and success of the project. McPhy Group will continue to focus on implementing its strategy, aiming to become one of the leading electrolyzer company in Europe, contributing to the ramp-up and development of low carbon hydrogen. ________________________________ ABOUT...

Corbion hereby reports the transaction details related to its € 20 million share buyback program announced on 26 April 2024. During the week of 20 May up to and including 24 May 2024 a total of 70,111 shares were repurchased at an average price of €20.7635 for a total amount of €1,455,751.78. To date, the total consideration for shares repurchased amounts to €6,304,382.81 representing 31.52% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progress of the share buyback program on its website: https://www.corbion.com/Investor-relations/shareholder-information This overview contains detailed information on the daily amount of repurchased shares and individual share purchase transactions.AttachmentWeekly progress on Corbion share buyback program 20 May – 24 May 2024 ...

  Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myelomaFDA Priority Review granted based on positive results from IMROZ phase 3 study If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care treatment for patients with newly diagnosed transplant-ineligible multiple myeloma Pivotal IMROZ phase 3 study results to be featured during oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingParis, May 27, 2024. The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with transplant-ineligible...

Perth, May 27, 2024 (GLOBE NEWSWIRE) — EXPLORATION UPDATE FOR MEYAS SAND GOLD PROJECT – SUDAN Perth, Western Australia/ May 27, 2024/Perseus Mining Limited (ASX/TSX: PRU) is pleased to provide an update on exploration activities and studies completed to date at its Meyas Sands Gold Project (MSGP) in Sudan. The full release with drill results tables and figures is available on www.perseusmining.com, www.asx.com.au and www.sedarplus.ca. Since acquiring the MSGP in May 2022, Perseus has focussed on the development of the Galat Sufur South (GSS) deposit, and when possible, has conducted infill resource definition drilling, sterilisation trenching and drilling, a passive seismic survey, hydrogeological, metallurgical, and geotechnical work in preparation for the inclusion of data in a Front-End Engineering and Design (FEED) Study...

Latest results for 94 new drillholes totalling 20,735m for Sayona’s Moblan Lithium Project, Québec, Canada with highlights including:South Pegmatites:40.70m @ 1.52% Li2O from 130.50m in drillhole 1331-23-537 78.20m @ 1.55% Li2O from 51.50m in drillhole 1331-23-679 57.05m @ 1.48% Li2O from 41.15m in drillhole 1331-23-684Inter Pegmatites:44.75m @ 1.41% Li2O from 250.15m in drillhole 1331-23-461 49.70m @ 1.61% Li2O from 143.30m in drillhole 1331-23-503 45.00m @ 1.17% Li2O from 291.50m in drillhole 1331-23-513Moleon Pegmatites:30.20m @ 1.73% Li2O from 158.80m in drillhole 1331-23-552 44.25m @ 1.29% Li2O from 214.00m in drillhole 1331-23-582 42.75m @ 1.85% Li2O from 176.80m in drillhole 1331-23-583A 36.85m @ 1.77% Li2O from 181.95m in drillhole 1331-23-584 43.90m @ 1.66% Li2O from 139.90m in drillhole 1331-23-585Potential...

72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract; Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater percentage of participants than placebo;BRISBANE, Calif., May 25, 2024 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced data presentations from its Phase 2b ORIGIN trial of atacicept in immunoglobulin A nephropathy (IgAN), showing that atacicept stabilized kidney function through 72 weeks and led to rapid improvements in hematuria. These data were presented at the 61st European Renal Association Congress (ERA24) being held in Stockholm. “For the first...